BRNS — Barinthus Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $55.06m
- -$50.87m
- $0.80m
- 13
- 46
- 15
- 12
Annual income statement for Barinthus Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.85 | 4.82 | 0.268 | 44.7 | 0.802 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 32.5 | 24.9 | 59.3 | 48.7 | 84.7 |
| Operating Profit | -25.7 | -20 | -59 | -4.04 | -83.9 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.7 | -17.8 | -51.1 | 0.85 | -76.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22.7 | -17.9 | -51.1 | 5.32 | -73.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -20.7 | -17.7 | -50.9 | 5.34 | -73.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -20.7 | -17.7 | -50.9 | 5.34 | -73.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.609 | -0.52 | -1.13 | 0.14 | -1.91 |